Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHA) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to -$34.3 million.

  • Innate Pharma's Operating Expenses rose 1764.53% to -$34.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$232.5 million, marking a year-over-year decrease of 4016.22%. This contributed to the annual value of $76.6 million for FY2024, which is 417.63% down from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Operating Expenses is -$34.3 million, which was up 1764.53% from -$76.6 million recorded in Q4 2024.
  • Innate Pharma's Operating Expenses' 5-year high stood at $8.7 million during Q2 2021, with a 5-year trough of -$83.0 million in Q4 2021.
  • Its 5-year average for Operating Expenses is -$43.4 million, with a median of -$41.6 million in 2024.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 11726.94% in 2021, then plummeted by 10565903.78% in 2023.
  • Over the past 5 years, Innate Pharma's Operating Expenses (Quarter) stood at -$83.0 million in 2021, then soared by 99.91% to -$75599.3 in 2022, then crashed by 105659.04% to -$80.0 million in 2023, then increased by 4.18% to -$76.6 million in 2024, then surged by 55.25% to -$34.3 million in 2025.
  • Its last three reported values are -$34.3 million in Q2 2025, -$76.6 million for Q4 2024, and -$41.6 million during Q2 2024.